Literature DB >> 26212008

CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer.

Y-C Wu1, S-J Tang2, G-H Sun3, K-H Sun1.   

Abstract

In the tumor microenvironment, chemokine system has a critical role in tumorigenesis and metastasis. The acquisition of stem-like properties by cancer cells is involved in metastasis and drug resistance, which are pivotal problems that result in poor outcomes in patients with lung cancer. Patients with advanced lung cancer present high plasma levels of transforming growth factor-β1 (TGFβ1), which correlate with poor prognostic features. Therefore, TGFβ1 may be important in the tumor microenvironment, where chemokines are widely expressed. However, the role of chemokines in TGFβ1-induced tumor progression still remains unclear. In our study, TGFβ1 upregulated CXC chemokine receptor expression, migration, invasion, epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) formation in lung adenocarcinoma. We found that CXCR7 was the most upregulated chemokine receptor induced by TGFβ1. CXCR7 knockdown resulted in reduction of migration, invasion and EMT induced by TGFβ1, whereas CXCR4 knockdown did not reverse TGFβ1-promoted EMT. CXCR7 silencing significantly decreased cancer sphere-forming capacity, stem-like properties, chemoresistance and TGFβ1-induced CSC tumor initiation in vivo. In clinical samples, high TGFβ1 and CXCR7 expression was significantly associated with the late stages of lung adenocarcinoma. Moreover, TGFβ1 and CXCR7 coexpression was positively correlated with the CSC marker, CD44, which is associated with lymph node metastasis. Besides, patients with high expression of both CXCR7 and TGFβ1 presented a significantly worse survival rate. These results suggest that the TGFβ1-CXCR7 axis may be a prognostic marker and may provide novel targets for combinational therapies to be used in the treatment of advanced lung cancer in the future.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26212008     DOI: 10.1038/onc.2015.274

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  RAC1 activation mediates Twist1-induced cancer cell migration.

Authors:  Wen-Hao Yang; Hsin-Yi Lan; Chi-Hung Huang; Shyh-Kuan Tai; Cheng-Hwai Tzeng; Shou-Yen Kao; Kou-Juey Wu; Mien-Chie Hung; Muh-Hwa Yang
Journal:  Nat Cell Biol       Date:  2012-03-11       Impact factor: 28.824

3.  The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes.

Authors:  Karl Balabanian; Bernard Lagane; Simona Infantino; Ken Y C Chow; Julie Harriague; Barbara Moepps; Fernando Arenzana-Seisdedos; Marcus Thelen; Françoise Bachelerie
Journal:  J Biol Chem       Date:  2005-08-17       Impact factor: 5.157

4.  Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta.

Authors:  Esther Bertran; Laia Caja; Estanis Navarro; Patricia Sancho; Jèssica Mainez; Miguel M Murillo; Antonia Vinyals; Angels Fabra; Isabel Fabregat
Journal:  Cell Signal       Date:  2009-07-06       Impact factor: 4.315

Review 5.  The chemokine system and cancer.

Authors:  Frances R Balkwill
Journal:  J Pathol       Date:  2011-11-23       Impact factor: 7.996

Review 6.  Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis.

Authors:  Magda Kucia; Ryan Reca; Katarzyna Miekus; Jens Wanzeck; Wojtek Wojakowski; Anna Janowska-Wieczorek; Janina Ratajczak; Mariusz Z Ratajczak
Journal:  Stem Cells       Date:  2005-05-11       Impact factor: 6.277

7.  Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma.

Authors:  Y Hasegawa; S Takanashi; Y Kanehira; T Tsushima; T Imai; K Okumura
Journal:  Cancer       Date:  2001-03-01       Impact factor: 6.860

Review 8.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

9.  CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Authors:  Zhenhua Miao; Kathryn E Luker; Bretton C Summers; Rob Berahovich; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Jeffrey J Essner; Aidas Nasevicius; Gary D Luker; Maureen C Howard; Thomas J Schall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-26       Impact factor: 11.205

10.  [Defective expression of TGFBR3 gene and its molecular mechanisms in non-small cell lung cancer cell lines].

Authors:  Xiefang Jiang; Rengyun Liu; Zhe Lei; Jiacong You; Qinghua Zhou; Hongtao Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-05
View more
  44 in total

1.  Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts.

Authors:  Babak Behnam Azad; Ala Lisok; Samit Chatterjee; John T Poirier; Mrudula Pullambhatla; Gary D Luker; Martin G Pomper; Sridhar Nimmagadda
Journal:  J Nucl Med       Date:  2016-02-23       Impact factor: 10.057

2.  14-3-3σ Gene Loss Leads to Activation of the Epithelial to Mesenchymal Transition Due to the Stabilization of c-Jun Protein.

Authors:  Kumarkrishna Raychaudhuri; Neelam Chaudhary; Mansa Gurjar; Roseline D'Souza; Jazeel Limzerwala; Subbareddy Maddika; Sorab N Dalal
Journal:  J Biol Chem       Date:  2016-06-03       Impact factor: 5.157

3.  Decursin inhibits tumor growth, migration, and invasion in gastric cancer by down-regulating CXCR7 expression.

Authors:  Solbi Kim; Ji-Eun Kim; Nayoung Kim; Mina Joo; Myung-Won Lee; Heung Jin Jeon; Hyewon Ryu; Ik-Chan Song; Gyu-Yong Song; Hyo Jin Lee
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

4.  Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.

Authors:  Achinto Saha; Songyeon Ahn; Jorge Blando; Fei Su; Mikhail G Kolonin; John DiGiovanni
Journal:  Cancer Res       Date:  2017-07-07       Impact factor: 12.701

5.  CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC.

Authors:  Jeffrey H Becker; Yandi Gao; Margaret Soucheray; Ines Pulido; Eiki Kikuchi; María L Rodríguez; Rutu Gandhi; Aranzazu Lafuente-Sanchis; Miguel Aupí; Javier Alcácer Fernández-Coronado; Paloma Martín-Martorell; Antonio Cremades; José M Galbis-Caravajal; Javier Alcácer; Camilla L Christensen; Patricia Simms; Ashley Hess; Hajime Asahina; Michael P Kahle; Fatima Al-Shahrour; Jeffrey A Borgia; Agustín Lahoz; Amelia Insa; Oscar Juan; Pasi A Jänne; Kwok-Kin Wong; Julian Carretero; Takeshi Shimamura
Journal:  Cancer Res       Date:  2019-07-04       Impact factor: 12.701

6.  CXCL12 Retargeting of an Oncolytic Adenovirus Vector to the Chemokine CXCR4 and CXCR7 Receptors in Breast Cancer.

Authors:  Samia M O'Bryan; J Michael Mathis
Journal:  J Cancer Ther       Date:  2021-06

7.  Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1.

Authors:  Y-L Hsu; J-Y Hung; W-A Chang; Y-S Lin; Y-C Pan; P-H Tsai; C-Y Wu; P-L Kuo
Journal:  Oncogene       Date:  2017-04-24       Impact factor: 9.867

8.  Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.

Authors:  Xin Tang; Xiang Li; Zitao Li; Yunshuang Liu; Lihong Yao; Shuang Song; Hongyan Yang; Caijuan Li
Journal:  Tumour Biol       Date:  2016-07-27

9.  IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma.

Authors:  Y Qiao; C Zhang; A Li; D Wang; Z Luo; Y Ping; B Zhou; S Liu; H Li; D Yue; Z Zhang; X Chen; Z Shen; J Lian; Y Li; S Wang; F Li; L Huang; L Wang; B Zhang; J Yu; Z Qin; Y Zhang
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

Review 10.  Epigenetically distinct sister chromatids and asymmetric generation of tumor initiating cells.

Authors:  Yongqing Liu; Laura Siles; Antonio Postigo; Douglas C Dean
Journal:  Cell Cycle       Date:  2018-10-13       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.